Designing next-generation interleukin immunotherapy: A cytokine-guided framework for precision cancer therapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Interleukins (ILs) are crucial for anti-tumor immunity but have limited clinical success due to imprecise delivery and targeting.
• First-generation cytokines like IL-2 showed potential but faced challenges with receptor selectivity, systemic exposure, and tumor immune context alignment.

Purpose of the Study:

• To review next-generation interleukins (IL-15, IL-21, IL-10) and their specialized roles in cancer immunotherapy.
• To explore strategies for optimizing cytokine deployment, including receptor-biased engineering and spatially restricted delivery.
• To propose a framework for cytokine-guided cancer immunotherapy integrating receptor logic, delivery, and immune context.

Main Methods:

• Review of current literature on interleukin-based cancer immunotherapy.
• Analysis of advances in cytokine engineering and delivery strategies.
• Synthesis of emerging approaches for context-matched combination therapy.

Main Results:

• Next-generation interleukins (IL-15, IL-21, IL-10) show promise in sustaining cytotoxic T cells, preserving effector function, and modulating suppressive immune states.
• Emerging strategies focus on receptor-biased engineering, localized delivery, and combination therapies tailored to the tumor microenvironment.
• Key barriers to clinical translation are shifting from molecular limitations to translational challenges like biomarker development and trial design.

Conclusions:

• Next-generation interleukins represent precisely deployable immunotherapeutic modules, not just stronger cytokines.
• A cytokine-guided framework integrating multiple factors is proposed for rational and durable cancer immunotherapy.
• Overcoming translational hurdles is critical for realizing the full potential of advanced interleukin therapies in cancer treatment.